Acute myeloid leukemia
Conditions
Interventions
Case series:Cladribine, homoharringtonine and cytarabine
Sponsors
Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. To be aged 18~55 years; 2. Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2; 3. Acute myeloid leukemia diagnosied by MICM criterion (rule out APL); 4. Primary AML; 5. Expected survival longer than 3 months; 6. Meets the diagnosis criterion of refractory AML: Didn't reach CR after two cycles of standard induction; With blasts/leukemic cell clearance lower than 50% after one cycle of standard induction; Relapse within 6 months after first CR; Relapse later than 6 months after first CR and didn't respond to the former induction regimen; Relapse more than 2 times; 7. Meets the diagnosis criterion of relapse AML: more than 5% blasts found in bone marrow/peripheral blood after CR(rule out other cause, consolidation etc.); 8. Bone marrow aspirtes show active proliferation and above 9. Signed written informed consent.
Exclusion criteria
Exclusion criteria: 1. Uncontrolled infection; 2. Other severe condition that patients can not tolerate chemotherapy; 3. Liver and renal insufficiency (creatinine, AST or ALT more than 2* upper normal serum level); 4. Severe neurological or psychiatric history; 5. Heart failure NYHA III/IV, severe arrhythmia, ejection fraction less than 50% by echocardiography; 6. Allergy to any drug in the CHA regimen; 7. Patients with a "currently active" second malignancy; 8. Patients underwent stem cell transplatation; 9. Patients with extra-medullary leukemia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission rate;partial remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Disease free survival;minimal residual disease; | — |
Countries
China
Contacts
Public ContactJunmin Li
Outcome results
None listed